ReviewExpert review of vaccines2012
Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses.
Review in Expert review of vaccines, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Cellular Immune Response in Horses After West Nile Neuroinvasive Disease.Animals : an open access journal from MDPI · 2025Article
- The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: A primer.Human vaccines & immunotherapeutics · 2024Review
- Vaccinations in patients with chronic lymphocytic leukemia.Seminars in hematology · 2024Review
- Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective.Bioanalysis · 2021Article
- Vaccine-Induced Cellular Immunity againstVaccines · 2021Review
- Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines.Frontiers in molecular biosciences · 2021Review
- Dose Dependent Antimicrobial Cellular Cytotoxicity-Implications forFrontiers in pharmacology · 2021Article
- An overview of immunoinformatics approaches and databases linking T cell receptor repertoires to their antigen specificity.Immunogenetics · 2020Review
- Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.Journal of virology · 2019Article
- Multivariate profiling of African green monkey and rhesus macaque T lymphocytes.Scientific reports · 2019Article
- Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials.Vaccines · 2018Article
- Review
- Beyond Passive Immunity: Is There Priming of the Fetal Immune System Following Vaccination in Pregnancy and What Are the Potential Clinical Implications?Frontiers in immunology · 2018Review
- Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release.Frontiers in immunology · 2018Article
- Review
- T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia.Blood advances · 2017Article
- A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
There is a need for novel approaches to tackle major vaccine challenges such as malaria, tuberculosis and HIV, among others. Success will require vaccines able to induce a cytotoxic T-cell response--a deficiency of most current vaccine approaches. The successful development of T-cell vaccines faces many hurdles, not least being the lack of consensus on a standardized T-cell assay format able to be used as a correlate of vaccine efficacy. Hence, there remains a need for reproducible measures of T-cell immunity proven in human clinical trials to correlate with vaccine protection. The T-cell equivalent of a neutralizing antibody assay would greatly accelerate the development and commercialization of T-cell vaccines. Recent advances have seen a plethora of new T-cell assays become available, including some like cytometry by time-of-flight with extreme multiparameter T-cell phenotyping capability. However, whether it is historic thymidine-based proliferation assays or sophisticated new cytometry assays, each assay has its relative advantages and disadvantages, and relatively few of these assays have yet to be validated in large-scale human vaccine trials. This review examines the current range of T-cell assays and assesses their suitability for use in human vaccine trials. Should one or more of these assays be accepted as an agreed surrogate of T-cell protection by a regulatory agency, this would significantly accelerate the development of T-cell vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.